---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-003801"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:10:50.043298+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Crinetics' atumelnant Phase 2 CAH trial meets primary endpoint with up to 80% mean A4 reduction

## Summary
- Atumelnant reduced androstenedione up to 80% (120mg, p<0.0001); 80mg dose reduced by 774 ng/dL (p<0.0001).
- Normalized testosterone in 8/13 females; 6 of 11 impacted participants resumed menses during the 12-week study.
- Total adrenal volume consistently reduced across all dose cohorts; polycythemia resolved in 5 of 6 impacted participants.
- No treatment-related severe or serious AEs; no dose reductions or discontinuations; most common AEs were headache (7/28) and fatigue (5/28).
- Crinetics plans to initiate a global Phase 3 pivotal trial in adults and a Phase 2b/3 pediatric study in 2025.

## SEC filing metadata
- accession: 0000950170-25-003801
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017025003801/0000950170-25-003801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017025003801/crnx-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-003801
- JSON: https://secwatch.observer/filing/0000950170-25-003801.json
- Plain text: https://secwatch.observer/filing/0000950170-25-003801.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.